E. Gustafsson, et al., "Identification of conformational epitopes for human IgG on Chemotaxis Inhibitory Protein of Staphylococcus aureus" BMC Immunology 10:13 (2009).
E. Gustafsson, et al., "Purification of truncated and mutated Chemotaxis Inhibitory Protein of Staphylococcus aureus--an anti-inflammatory protein," Protein Expr Purif. 63(2), 95 (2009).
E. Dahlen, et al., "Development of interleukin-1 receptor antagonist mutants with enhanced antagonistic activity in vitro and improved therapeutic efficacy in collagen-induced arthritis," J Immunotoxicol. 5(2), 189 (2008).
A. Malmborg, C. Furebring, and P. Stas, "Life After Death," EBR Spring ed, 76 (2007).
W. Knecht, J. Willemse, H. Stenhamre, M. Andersson, P. Berntsson, C. Furebring, A. Harrysson, A.-C. Malmborg-Hager, B.-M. Wissing, D. Hendriks and P. Cronet "Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis," FEBS J. 273(4), 778 (2006).
C. J. de Haas, et al., "Chemotaxis Inhibitory Protein of Staphylococcus aureus, a Bacterial Antiinflammatory Agent," 199(5), 687 (2004).
B. Postma, et al., "Chemotaxis inhibitory protein of Staphylococcus aureus binds specifically to the C5a and formylated peptide receptor," 172(11), 6994 (2004).